PM011 “Athlete's Heart” in Paediatric Age. Echocardiographic Evaluation in Athlete ChildrenRodriguez-Lopez · Global Heart2016PDF209 KB
513 POSTER Pharmacokinetic Evaluation of a Novel Anti-tumor Agent, PM01120Yin · European Journal of Cancer Supplements2006PDF57 KB
220 Lurbinectedin (PM01183): Antineoplastic Activity in Murine and Human Experimental ModelsFrapolli · European Journal of Cancer2012PDF80 KB
222 Lurbinectedin (PM01183): Pharmacokinetics/Pharmacodynamic (PK/PD) Properties in Pancreas, Ovarian and NSCLC XenograftsAviles · European Journal of Cancer2012PDF62 KB
223 Lurbinectedin (PM01183) Synergizes with Gemcitabine in NSCLC, Ovarian and Pancreas Tumor XenograftsMangues · European Journal of Cancer2012PDF78 KB
218 TC-NER Dependent Degradation of RNA Pol II in Response to Lurbinectedin (PM01183)Santamaría · European Journal of Cancer2012PDF62 KB
First-In-Human Phase I Study of Lurbinectedin (PM01183) in Patients with Advanced Solid TumorsElez · Clinical Cancer Research2014PDF1.7 MB
221 Lurbinectedin (PM01183) in Combination with Gemcitabine in Patient-Derived, Pancreatic Ductal Adenocarcinoma (PDA) XenograftsLópez-Casas · European Journal of Cancer2012PDF62 KB
335 Lurbinectedin (PM01183) in Combination with Paclitaxel (P) in Patients (pts) with Advanced Solid TumorsGarralda · European Journal of Cancer2015PDF62 KB
434 First-in-man Phase I Study of PM01183 Using an Accelerated Titration DesignRatain · European Journal of Cancer Supplements2010PDF63 KB
PM01183 Inhibits Myeloid-Derived Suppressor Cells In Vitro and In VivoKuroda · Future Medicine2017PDF1.4 MB
Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic SyndromeBenton · Hematological Oncology2018PDF673 KB
